Literature DB >> 25892861

Optimum chemotherapy for the management of advanced biliary tract cancer.

Marwan Ghosn1, Hampig Raphael Kourie1, Elie El Rassy1, Ralph Chebib1, Fadi El Karak1, Colette Hanna1, Dolly Nasr1.   

Abstract

Biliary tract cancers (BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis. The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status. Despite clinical trials studying many chemotherapeutic regimens and targeted therapies for the treatment of BTC, the standard of care for advanced BTC remains the combination of gemcitabine with cisplatin. Many new molecules targeting proliferation and survival pathways, the immune response and angiogenesis are currently undergoing phase I and II trials for the treatment of advanced BTC with promising results.

Entities:  

Keywords:  Biliary tract cancer; Chemotherapy; Novel therapies; Treatment modalities; Updates

Mesh：

Year:  2015        PMID： 25892861      PMCID： PMC4394072          DOI： 10.3748/wjg.v21.i14.4121

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  32 in total

1.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

2.  Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma.

Authors:  Koichi Shimizu; Yoshihito Kotera; Atsushi Aruga; Nobuhiro Takeshita; Ken Takasaki; Masakazu Yamamoto
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-03       Impact factor: 7.027

3.  Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.

Authors:  L H Jensen; J Lindebjerg; J Ploen; T F Hansen; A Jakobsen
Journal:  Ann Oncol       Date:  2012-02-23       Impact factor: 32.976

4.  A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Ichiro Yasuda; Nobuo Toda; Hirofumi Kogure; Keiji Hanada; Hiroyuki Maguchi; Naoki Sasahira; Hideki Kamada; Tsuyoshi Mukai; Yoshihiro Okabe; Osamu Hasebe; Iruru Maetani; Kazuhiko Koike
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-26       Impact factor: 3.333

5.  Phase II study of erlotinib in patients with advanced biliary cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

6.  Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.

Authors:  J W Valle; J Furuse; M Jitlal; S Beare; N Mizuno; H Wasan; J Bridgewater; T Okusaka
Journal:  Ann Oncol       Date:  2013-12-18       Impact factor: 32.976

7.  Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.

Authors:  M Higashi; S Yonezawa; J J Ho; S Tanaka; T Irimura; Y S Kim; E Sato
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

8.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

9.  Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

Authors:  Atul Sharma; Amit Dutt Dwary; Bidhu Kalyan Mohanti; Surya V Deo; Sujoy Pal; Vishnu Sreenivas; Vinod Raina; Nootan Kumar Shukla; Sanjay Thulkar; Pramod Garg; Surendra Pal Chaudhary
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

10.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Authors:  Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333
View more
  6 in total

Review 1.  Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era.

Authors:  Megan R D'Andrea; Corey M Gill; Melissa Umphlett; Nadejda M Tsankova; Mary Fowkes; Joshua B Bederson; Priscilla K Brastianos; Raj K Shrivastava
Journal:  Oncologist       Date:  2019-11-06

2.  Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs Against Cisplatin-Resistant Cancer Cells and Human Mesenchymal Stem Cells.

Authors:  Marisol Gouveia; João Figueira; Manuel G Jardim; Rita Castro; Helena Tomás; Kari Rissanen; João Rodrigues
Journal:  Molecules       Date:  2018-06-17       Impact factor: 4.411

3.  Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.

Authors:  Kwai Han Yoo; Nayoung K D Kim; Woo Il Kwon; Chung Lee; Sun Young Kim; Jiryeon Jang; Jungmi Ahn; Mihyun Kang; Hyojin Jang; Seung Tae Kim; Soomin Ahn; Kee-Taek Jang; Young Suk Park; Woong-Yang Park; Jeeyun Lee; Jin Seok Heo; Joon Oh Park
Journal:  Transl Oncol       Date:  2016-04-22       Impact factor: 4.243

4.  Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis.

Authors:  Sheng Zhao; Yanping Miao; Ruijun Wang; Haidong Guo; Feng Jin; Xiuling Guo; Tianyou Luo
Journal:  Onco Targets Ther       Date:  2016-10-28       Impact factor: 4.147

5.  Effect of midkine on gemcitabine resistance in biliary tract cancer.

Authors:  Yongliang Lu; Bing Yan; Huihui Guo; Li Qiu; Xinrong Sun; Xiang Wang; Qian Shi; Ying Bao
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

6.  The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study.

Authors:  Caiyun Nie; Huifang Lv; Yishu Xing; Beibei Chen; Weifeng Xu; Jianzheng Wang; Xiaobing Chen
Journal:  BMC Cancer       Date:  2021-02-23       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.